Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - A retrospective analysis

被引:32
作者
Bartsch, Rupert
Fromm, Sabine
Rudas, Margaretha
Wenzel, Catharina
Harbauer, Stefanie
Roessler, Karl
Kitz, Klaus
Steger, Guenther G.
Weitmann, Hajo-Dirk
Poetter, Richard
Zielinski, Christoph C.
Dieckmann, Karin
机构
[1] Med Univ Vienna, Dept Radiotherapy & Radiobiol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Pathol, Vienna, Austria
[3] Med Univ Vienna, Dept Internal Med 1, Div Oncol, Vienna, Austria
[4] Med Univ Vienna, Dept Neurosurg, Vienna, Austria
关键词
advanced breast cancer; brain metastases; whole brain radiotherapy; systemic palliative treatment;
D O I
10.1016/j.radonc.2006.08.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Brain metastases have evolved from a rare to a frequently encountered event in advanced breast cancer due to advances in palliative systemic treatment. Patients and methods: All Patients treated at our centre from 1994 to 2004 with WBRT for brain metastases from breast cancer were included. We performed a multivariate analysis (Cox regression) to explore which factors are able to influence significantly cerebral time to progression (TTP) and overall survival (metastatic sites [visceral versus non-visceral], Karnofsky performance score [KPS], age, intensified local treatment [boost irradiation, neuro-surgical resection] further systemic treatment). Results: Overall 174 patients, median age 51 years, range 27-76 years, were included. Median TTP was 3 months (m), range 1-33+ m. Median overall survival was 7 m, range 1-44 m. Factors significantly influencing TTP were KPS (p = 0.002), intensified local treatment (p < 0.001), and palliative systemic treatment (p = 0.001). Factors significantly influencing survival were intensified local treatment (p = 0.004), metastatic sites (p = 0.008), KPS (p = 0.006), and palliative systemic treatment (p < 0.001). Conclusion: As shown by the significant influence of metastatic sites, some patients die from their advanced systemic tumour situation before they would die from cerebral progression. In other individuals however, intensified local treatment and systemic treatment appear to influence cerebral time to progression and overall survival. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:313 / 317
页数:5
相关论文
共 48 条
[1]   Radiosurgery for brain metastases: the Tuebingen experience [J].
Becker, G ;
Jeremic, B ;
Engel, C ;
Buchgeister, M ;
Paulsen, F ;
Duffner, F ;
Meisner, C ;
Bamberg, M .
RADIOTHERAPY AND ONCOLOGY, 2002, 62 (02) :233-237
[2]   Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma [J].
Bendell, JC ;
Domchek, SM ;
Burstein, HJ ;
Harris, L ;
Younger, J ;
Kuter, I ;
Bunnell, C ;
Rue, M ;
Gelman, R ;
Winer, E .
CANCER, 2003, 97 (12) :2972-2977
[3]   SURGICAL-TREATMENT OF MULTIPLE BRAIN METASTASES [J].
BINDAL, RK ;
SAWAYA, R ;
LEAVENS, ME ;
LEE, JJ .
JOURNAL OF NEUROSURGERY, 1993, 79 (02) :210-216
[4]  
BOOGERD W, 1992, CANCER, V69, P972, DOI 10.1002/1097-0142(19920215)69:4<972::AID-CNCR2820690423>3.0.CO
[5]  
2-P
[6]   PALLIATION OF BRAIN METASTASES - FINAL RESULTS OF THE 1ST 2 STUDIES BY THE RADIATION-THERAPY-ONCOLOGY-GROUP [J].
BORGELT, B ;
GELBER, R ;
KRAMER, S ;
BRADY, LW ;
CHANG, CH ;
DAVIS, LW ;
PEREZ, CA ;
HENDRICKSON, FR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1980, 6 (01) :1-9
[7]   Cancer incidence and mortality in Europe, 2004 [J].
Boyle, P ;
Ferlay, J .
ANNALS OF ONCOLOGY, 2005, 16 (03) :481-488
[8]   Survival following whole brain radiation treatment for cerebral metastases: an audit of 474 patients [J].
Broadbent, AM ;
Hruby, G ;
Tin, MM ;
Jackson, M ;
Firth, I .
RADIOTHERAPY AND ONCOLOGY, 2004, 71 (03) :259-265
[9]   Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer [J].
Clayton, AJ ;
Danson, S ;
Jolly, S ;
Ryder, WDJ ;
Burt, PA ;
Stewart, AL ;
Wilkinson, PM ;
Welch, RS ;
Magee, B ;
Wilson, G ;
Howell, A ;
Wardley, AM .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :639-643
[10]  
DISTEFANO A, 1979, CANCER, V44, P1913, DOI 10.1002/1097-0142(197911)44:5<1913::AID-CNCR2820440554>3.0.CO